Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma

Autor: Bryn Pressnail, Ari M. Vanderwalde, Nancy L. Bartlett, Mitchell R. Smith, Paul G. Montgomery, Jonathan W. Friedberg, Ann S. LaCasce, Tricia Ellis, Anthony J. Dodds, Peter Martin, Jeff Szer, Richard van der Jagt, Saurabh Rajguru, Michael D. Williams, Zhengming Chen, Michael Bar, Kristen N. Ganjoo, Katherine Sue Robinson, Fernando Cabanillas, John P. Leonard, Robin Joyce, Jordan A. Herst, Bruce D. Cheson, Bernard Lemieux
Rok vydání: 2017
Předmět:
Adult
Male
Bendamustine
Oncology
medicine.medical_specialty
Time Factors
medicine.medical_treatment
Follicular lymphoma
Disease-Free Survival
Article
Lymphoplasmacytic Lymphoma
03 medical and health sciences
0302 clinical medicine
hemic and lymphatic diseases
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Bendamustine Hydrochloride
Humans
Multicenter Studies as Topic
Antineoplastic Agents
Alkylating
Aged
Aged
80 and over
Clinical Trials as Topic
Chemotherapy
business.industry
Lymphoma
Non-Hodgkin
Neoplasms
Second Primary
Hematology
Middle Aged
medicine.disease
Hematopoietic Stem Cell Mobilization
Lymphoma
Clinical trial
Leukemia
Myeloid
Acute
Treatment Outcome
Myelodysplastic Syndromes
030220 oncology & carcinogenesis
Female
Mantle cell lymphoma
Rituximab
business
030215 immunology
medicine.drug
Zdroj: British Journal of Haematology. 178:250-256
ISSN: 0007-1048
DOI: 10.1111/bjh.14667
Popis: Summary Despite the long history of bendamustine as treatment for indolent non-Hodgkin lymphoma, long-term efficacy and toxicity data are minimal. We reviewed long-term data from three clinical trials to characterize the toxicity and efficacy of patients receiving bendamustine. Data were available for 149 subjects at 21 sites. The median age was 60 years at the start of bendamustine (range 39–84), and patients had received a median of 3 prior therapies. The histologies included grades 1–2 follicular lymphoma (FL; n = 73), grade 3 FL (n = 23), small lymphocytic lymphoma (n = 20), marginal zone lymphoma (n = 15), mantle cell lymphoma (n = 9), transformed lymphomas (n = 5), lymphoplasmacytic lymphoma (n = 2) and not reported (n = 2). The median event-free survival was 14·1 months. Nine of 12 attempted stem cell collections were successful. With a median follow-up of 8·9 years, 23 patients developed 25 cancers, including 8 patients with myelodysplastic syndrome/acute myeloid leukaemia. These data provide important information regarding the long-term toxicity of bendamustine in previously treated patients. A small but meaningful number of patients achieved durable remissions following bendamustine. These rigorously collected, patient-level, long-term follow-up data provide reassurance that bendamustine or bendamustine plus rituximab is associated with efficacy and safety for patients with relapsed or refractory indolent non-Hodgkin lymphoma.
Databáze: OpenAIRE
Externí odkaz: